Jazz Pharmaceuticals plc Operating Income Loss

• Jazz Pharmaceuticals plc showed a decrease of -160.0% in Operating Income Loss from 2024 to 2025.
• This data is from Jazz Pharmaceuticals plc's annual report (Form 10-K), filed with the SEC on February 24, 2026.
• XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 17 years of available data (2009 to 2025), Jazz Pharmaceuticals plc's Operating Income Loss has declined by 2,800.8%.
• Historical annual values: Fiscal year 2025: -$430.24 million | Fiscal year 2024: $716.63 million | Fiscal year 2023: $578.58 million | Fiscal year 2022: -$65.53 million | Fiscal year 2021: $170.28 million | Fiscal year 2020: $378.07 million | Fiscal year 2019: $532.37 million | Fiscal year 2018: $614.84 million | Fiscal year 2017: $528.84 million | Fiscal year 2016: $591.65 million | Fiscal year 2015: $508.22 million | Fiscal year 2014: $195.59 million | Fiscal year 2013: $340.31 million | Fiscal year 2012: $197.84 million | Fiscal year 2011: $127.83 million | Fiscal year 2010: $57.79 million | Fiscal year 2009: $15.93 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026